Annexon, Inc. filed a current report on August 10, 2026, disclosing the resignation of director Muneer Satter and the simultaneous appointment of Mark S. Blumenkranz, M.D., M.S.S., to its board of directors, effective the same date.

Key Highlights

  • Director resigned: Muneer Satter stepped down from the board, the audit committee, and as chair of the nominating and corporate governance committee, effective immediately prior to the appointment of his replacement.
  • New director appointed: Mark S. Blumenkranz, M.D., M.S.S., was appointed to the board on August 10, 2026, as a Class II director with a term expiring at the 2028 annual meeting of stockholders.
  • Committee assignments: Dr. Blumenkranz was appointed as a member of the audit committee and the science and technology committee of the board.
  • Initial stock option grant: In lieu of the standard automatic initial grant, Dr. Blumenkranz received a stock option to purchase 175,000 shares of common stock under the company's 2020 Incentive Award Plan.
  • Annual compensation: Dr. Blumenkranz will receive a $40,000 annual retainer and, at each annual stockholder meeting, an automatic grant of a stock option to purchase 65,000 shares of common stock.
  • No disagreement cited: The filing states Mr. Satter's resignation "was not the result of any disagreement with the Company on any matter related to the Company's operations, policies, practices or strategy, the Company's management or the Board."

Annexon Board Transition: Satter Departs After Eleven Years, Blumenkranz Joins

According to the filing, Muneer Satter notified Annexon, Inc. of his resignation on August 10, 2026, stepping down from the board of directors, the audit committee, and his role as chair of the nominating and corporate governance committee. The company's management and board acknowledged "more than eleven years of distinguished service on the Board and many positive contributions to the Company." The filing explicitly states his departure was not related to any disagreement with the company on matters of operations, policies, practices, strategy, management, or the board.

Effective the same date, the board appointed Mark S. Blumenkranz, M.D., M.S.S., as a Class II director, based on the recommendation of the nominating and corporate governance committee. Dr. Blumenkranz will serve until the 2028 annual meeting of stockholders and until his successor has been elected and qualified, according to the filing. He was also named to the audit committee and the science and technology committee.

Under the company's non-employee director compensation program, the filing discloses that Dr. Blumenkranz will receive a $40,000 annual retainer and an automatic annual stock option grant to purchase 65,000 shares of common stock, vesting on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. On his appointment date, and in lieu of the standard automatic initial grant, he received a stock option to purchase 175,000 shares of common stock under the 2020 Incentive Award Plan. The filing also notes Dr. Blumenkranz entered into the company's standard indemnification and advancement agreement for directors and executive officers. The company stated it is not aware of any transaction involving Dr. Blumenkranz requiring disclosure under Item 404(a) of Regulation S-K, and that no arrangement or family relationship exists that influenced his selection.

What Was Disclosed

Annexon, Inc. (Nasdaq: ANNX) reported a director resignation and a new director appointment, each effective August 10, 2026, along with the new director's committee assignments, stock option grants, and compensation terms under the company's non-employee director program.